Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally
Portfolio Pulse from Nina Zdinjak
Enveric Biosciences (NASDAQ:ENVB) announced positive preclinical results for its non-hallucinogenic psychedelic drug candidate EB-003, which can be administered orally. The company plans to advance EB-003 to clinical trials by the end of 2025. Enveric also recently obtained a US patent for another drug candidate, EB-002, aimed at treating neurological disorders.
July 25, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enveric Biosciences announced positive preclinical results for its non-hallucinogenic psychedelic drug candidate EB-003, which can be administered orally. The company plans to advance EB-003 to clinical trials by the end of 2025. Enveric also obtained a US patent for another drug candidate, EB-002.
The positive preclinical results and the potential for oral administration of EB-003 are significant milestones for Enveric Biosciences. This news, combined with the recent US patent for EB-002, is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100